MCB Professor David Raulet, Univ. of Ottawa & Ottawa Hospital's Michele Ardolino and their colleagues' paper in The Journal of Clinical Investigation describes the important role Natural Killer (NK) cells may play in targeting tumors when combined with cancer immunotherapy drugs called checkpoint inhibitors.

They are currently investigating approaches to further enhance the cancer-killing ability of NK cells, and hope to someday profile how an individual's immune system interacts with their cancer, enabling more personalized immunotherapy treatments.


Credit: Juan Gaertner/Science Source